Table II.
Adjustment of therapy during the 16-week follow-up.⁎
| Week of follow-up | AML 5+ OLM 20 | AML 5+ OLM 40 | AML 5+ OLM 20/HCTZ 12.5 | Total |
|---|---|---|---|---|
| n | ||||
| 0 | 409 | 0 | 0 | 409 |
| 8 | 344 | 30 | 22 | 406 |
| 10 | 344 | 30 | 22 | 406 |
| 12 | 331 | 34 | 27 | 407 |
| 16 | 331 | 34 | 27 | 407 |
AML 5 = amlodipine 5 mg/d; HCTZ 12.5 = hydrochlorothiazide 12.5 mg/d; OLM 20 = olmesartan medoxomil 20 mg/d; OLM 40 = olmesartan medoxomil 40 mg/d.
⁎
The dosing regimen was altered at Week 8 or Week 12 once based on different patients’ medical conditions. All data were collected from the full analysis set group.